McKinney P A, Cartwright R A, Stiller C A, Hopton P A, Mann J R, Birch J M, Hartley A L, Waterhouse J A, Johnston H E
Br J Cancer. 1985 Dec;52(6):923-9. doi: 10.1038/bjc.1985.278.
Attention has recently focused on the possible teratogenic effects of the combination antiemetic doxylamine succinate, dicyclomine hydrochloride and pyridoxine hydrochloride (Debendox/Bendectin) prescribed to pregnant women. The Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC), a case-control investigation has analysed data derived from interview reports and medical records of 555 mothers of children (under 15 years) with cancer and 1110 mothers of matched control children. Separate analyses of interview reports and medical records both suggested that antiemetic ingestion during the index pregnancy does not increase the risk of developing childhood malignant disease in the exposed foetus. No dose-response relationship was evident. The lack of any significant relative risks held good for diagnostic sub-groups and when the trimester of ingestion was considered. Our results suggest that antimetics of this type are unlikely to be transplacental carcinogens.
最近，人们的注意力集中在给孕妇开的复合止吐药琥珀酸多西拉敏、盐酸双环胺和盐酸吡哆醇（Debendox/Bendectin）可能产生的致畸作用上。儿童癌症区域间流行病学研究（IRESCC）是一项病例对照调查，分析了来自555名患癌儿童（15岁以下）母亲的访谈报告和病历数据，以及1110名匹配对照儿童母亲的数据。对访谈报告和病历的单独分析均表明，在本次孕期摄入止吐药不会增加暴露胎儿患儿童恶性疾病的风险。未发现剂量反应关系。对于诊断亚组以及考虑摄入药物的孕期时，缺乏任何显著的相对风险这一情况依然成立。我们的结果表明，这类止吐药不太可能是经胎盘致癌物。
